RARE / Ultragenyx: Despite OI Trial Doubts, This Is A Robust Rare Disease Company

Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Joshua Higa - Vice Pr more_horizontal

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisi more_horizontal

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help t more_horizontal

The estate of Henrietta Lacks filed a lawsuit in Maryland federal court on Thursday accusing biopharmaceutical company Ultragenyx Pharmaceutical of un more_horizontal

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track more_horizontal

Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2023, it might be worth consid more_horizontal

NOVATO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the developmen more_horizontal

Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients wit more_horizontal